Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $56.57M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.63M
Average 0.42M
CRBP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 37.8% from a year ago
Cash & equivalents stood at $26.05M at the end of Q1 FY2026, up 37.8% from a year earlier and down 8.6% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.
Context
- Cash & equivalents amounted to 18.0% of total assets at the end of Q1 FY2026, up 4.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +37.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 28.49M USD
- Year-over-year change
- +65.7%
- 4-year CAGR
- +3.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.49M | +65.7% |
| FY2024 | 2024-12-31 | 17.2M | +25.3% |
| FY2023 | 2023-12-31 | 13.72M | -19.3% |
| FY2022 | 2022-12-31 | 17M | -32.0% |
| FY2021 | 2021-12-31 | 25.01M | — |
Cash & Equivalents vs competitors
How CRBP compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +37.8% is the 3rd highest of 10, against a peer median of -3.5%.
- Cash & equivalents amounts to 18.0% of total assets for CRBP, versus a peer median of 36.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 78.53M CHF | -3.5% | -2.0% | 89.9% | |
| Mar 2026 | $76.96M USD | +102.7% | -24.7% | 32.1% | |
| Mar 2026 | $71.32M USD | +58.2% | +112.3% | 36.8% | |
| Mar 2026 | $58.22M USD | +27.0% | +23.3% | 86.6% | |
| Mar 2026 | $42.15M USD | -3.4% | -30.7% | 27.0% | |
| Dec 2025 | €28.08M EUR | -57.7% | -30.7% | 44.8% | |
| Mar 2026 | $26.05M USD | +37.8% | +18.8% | 18.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $14.95M USD | -18.5% | +33.5% | 65.9% |
| Mar 2026 | $9.64M USD | -4.6% | -11.7% | 18.6% | |
| Mar 2026 | $8.54M USD | -64.5% | +2.2% | 17.4% | |
| Peer median (excluding CRBP) | — | -3.5% | -2.0% | 36.8% | |
Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.01M | 17M | 13.72M | 17.2M | 28.49M |
| Short-term Investments | 72.64M | 42.19M | 7.18M | 131.86M | 134.78M |
| Net Receivables | 0 | 0 | 0 | 0 | 1.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 192.48K | 192.48K | 192K | 3.91M | 1.52M |
| Total Current Assets | 100.2M | 60.18M | 23.55M | 152.98M | 166.95M |
| Property, Plant & Equipment (Net) | 7M | 5.5M | 4.04M | 2.52M | 1.24M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 523.81K | 632.77K | 690K | 385K | 0 |
| Total Non-current Assets | 7.53M | 6.13M | 4.73M | 2.9M | 1.24M |
| Total Assets | 107.73M | 66.31M | 28.27M | 155.88M | 168.2M |
| Account Payables | 1.78M | 2.17M | 3.18M | 4.79M | 2.22M |
| Short-term Debt | 3.86M | 3.15M | 16.21M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 133.71K | 36.87K | 39K | 2.28M | 2.86M |
| Total Current Liabilities | 17.01M | 12.64M | 31.89M | 11.82M | 20.69M |
| Long-term Debt | 15.64M | 15.98M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 22.21K | 22.21K | 44K | 0 | 0 |
| Total Non-current Liabilities | 21.61M | 20.68M | 3.28M | 1.63M | 0 |
| Total Liabilities | 38.62M | 33.32M | 35.18M | 13.45M | 20.69M |
| Common Stock | 12.52K | 417 | 0 | 1K | 2K |
| Retained Earnings | (349.73M) | (392.08M) | (436.68M) | (476.89M) | (555.43M) |
| Accumulated OCI | (62.45K) | (126.09K) | (1K) | 35K | (53K) |
| Other Stockholders Equity | 0 | 0 | (0) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 69.11M | 32.99M | (6.91M) | 142.43M | 147.5M |
| Total Debt | 26.59M | 25.09M | 20.89M | 3.24M | 1.63M |
| Net Debt | 1.58M | 8.09M | 7.16M | (13.96M) | (26.86M) |
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.